Skip to main content
NewslettersWatchlist

Intellipharmaceutics International Inc(IPCI-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0800
Day High0.0950
Open:0.0950
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
AI-generated - The Globe and Mail
IntelliPharmaCeutics Intl: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (IPCI)
AI-generated - The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
AI-generated - The Globe and Mail
IntelliPharmaCeutics Intl: Bottom 25 Performing Stocks Year-to-Date on TSX (IPCI)
ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2023 Results
ACCESSWIRE
Intellipharmaceutics Reports Director Election Results
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2023 Results
The Globe and Mail
IntelliPharmaCeutics Intl: Bottom 25 Performing Stocks Year-to-Date on TSX (IPCI)
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Nano Cap Stocks on TSX (IPCI)
Baystreet
Stocks in play: Intellipharmaceutics International Inc.
Newswire.ca
Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results
Newswire.ca
Intellipharmaceutics Announces Cease Trade Order
Newswire.ca
Intellipharmaceutics Provides Update on Management Cease Trade Order Application and Anticipates Cease Trade Order
Newswire.ca
Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2022 Results
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks (IPCI)
The Globe and Mail
IntelliPharmaCeutics Intl: Top 10 Undervalued Biotechnology Industry Stocks on TSE (IPCI)
ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
AccessWire
Intellipharmaceutics Announces Second Quarter 2022 Results
Baystreet
Stocks in play: Intellipharmaceutics International Inc.
AccessWire
Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022
AccessWire
Intellipharmaceutics Reports Director Election Results
AccessWire
Intellipharmaceutics Announces First Quarter 2022 Results
AccessWire
Intellipharmaceutics Announces Fiscal Year 2021 Results
AccessWire
Intellipharmaceutics Reports Director Election Results
AccessWire
Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
AccessWire
Intellipharmaceutics Comments on Recent Trading Activity
AccessWire
Intellipharmaceutics Announces Second Quarter 2021 Results
AccessWire
Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

Profile

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.